Obesity impairs sodium excretion through multiple mechanisms (RAAS activation, leptin effects, inflammatory signaling)
Anecdotal reports include increased tooth decay, gum inflammation, tooth sensitivity, dry mouth, bad breath, and tooth discolouration
Defense teams also attack causation, arguing that a patients high-fat diet, preexisting conditions, or genetics could explain the disease
Its hard to think, if its 2030, and we have many of these medicines that weve proven the benefits for chronic diseases and the government said its worth it after this two-year pilot theyre doing its hard to think of too many employers who would say, Thats not for me, Ricks told me
Specifically, the company states that FDA-approved GLP-1/GIP medications for weight loss and type 2 diabetes, including Ozempic, Wegovy, Zepbound, and Mounjaro, "may also be eligible for coverage." The company further states that while they "assist with prior authorizations and prescription submissions," they "do not bill insurance directly." This distinction is important: the compounded GLP-1 program itself is described as a cash-pay arrangement, but the company also facilitates access to FDA-approved branded medications that may have insurance pathways
Like all GLP 1 medicines, it works best when combined with sustainable changes to nutrition, activity, sleep, and eating habits